Minjae Kim, Hongseok Choi, Akshata Nayak, Sushil K. Tripathi, Vikas R. Aswar, Vidyasagar B. Gaikwad, Kenneth A. Jacobson and Lak Shin Jeong*,
{"title":"截短的 4′-硒核苷的结构-活性关系:A3 腺苷受体的活性和结合选择性","authors":"Minjae Kim, Hongseok Choi, Akshata Nayak, Sushil K. Tripathi, Vikas R. Aswar, Vidyasagar B. Gaikwad, Kenneth A. Jacobson and Lak Shin Jeong*, ","doi":"10.1021/acsmedchemlett.4c0034410.1021/acsmedchemlett.4c00344","DOIUrl":null,"url":null,"abstract":"<p >This study explored the impact of structural modifications on truncated 4′-selenonucleosides as ligands for the A<sub>3</sub> adenosine receptor (AR). We synthesized and evaluated a series of these compounds for their binding affinities, functional activities, and structural interactions by using computational modeling. The SAR study revealed that all compounds exhibited selective and notable hA<sub>3</sub>AR binding, among which <b>6l</b> (<i>K</i><sub>i</sub> = 5.2 nM) and <b>6m</b> (<i>K</i><sub>i</sub> = 5.7 nM) were found as the best binding compounds. The representative <i>N</i><sup>6</sup>-cyclopropyl compound <b>6m</b> was found to be a partial agonist, contrasting with the antagonist profiles of truncated 4′-oxo and 4′-thionucleosides. Computational docking highlighted <b>6m</b>’s unique interaction with Thr94 at the A<sub>3</sub>AR binding site. This research not only advances our understanding of A<sub>3</sub>AR ligand interactions but also highlights the potential of truncated 4′-selenonucleosides as effective A<sub>3</sub>AR modulators.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"15 9","pages":"1620–1626 1620–1626"},"PeriodicalIF":4.0000,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Structure–Activity Relationship of Truncated 4′-Selenonucleosides: A3 Adenosine Receptor Activity and Binding Selectivity\",\"authors\":\"Minjae Kim, Hongseok Choi, Akshata Nayak, Sushil K. Tripathi, Vikas R. Aswar, Vidyasagar B. Gaikwad, Kenneth A. Jacobson and Lak Shin Jeong*, \",\"doi\":\"10.1021/acsmedchemlett.4c0034410.1021/acsmedchemlett.4c00344\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >This study explored the impact of structural modifications on truncated 4′-selenonucleosides as ligands for the A<sub>3</sub> adenosine receptor (AR). We synthesized and evaluated a series of these compounds for their binding affinities, functional activities, and structural interactions by using computational modeling. The SAR study revealed that all compounds exhibited selective and notable hA<sub>3</sub>AR binding, among which <b>6l</b> (<i>K</i><sub>i</sub> = 5.2 nM) and <b>6m</b> (<i>K</i><sub>i</sub> = 5.7 nM) were found as the best binding compounds. The representative <i>N</i><sup>6</sup>-cyclopropyl compound <b>6m</b> was found to be a partial agonist, contrasting with the antagonist profiles of truncated 4′-oxo and 4′-thionucleosides. Computational docking highlighted <b>6m</b>’s unique interaction with Thr94 at the A<sub>3</sub>AR binding site. This research not only advances our understanding of A<sub>3</sub>AR ligand interactions but also highlights the potential of truncated 4′-selenonucleosides as effective A<sub>3</sub>AR modulators.</p>\",\"PeriodicalId\":20,\"journal\":{\"name\":\"ACS Medicinal Chemistry Letters\",\"volume\":\"15 9\",\"pages\":\"1620–1626 1620–1626\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2024-08-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Medicinal Chemistry Letters\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acsmedchemlett.4c00344\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Medicinal Chemistry Letters","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acsmedchemlett.4c00344","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Structure–Activity Relationship of Truncated 4′-Selenonucleosides: A3 Adenosine Receptor Activity and Binding Selectivity
This study explored the impact of structural modifications on truncated 4′-selenonucleosides as ligands for the A3 adenosine receptor (AR). We synthesized and evaluated a series of these compounds for their binding affinities, functional activities, and structural interactions by using computational modeling. The SAR study revealed that all compounds exhibited selective and notable hA3AR binding, among which 6l (Ki = 5.2 nM) and 6m (Ki = 5.7 nM) were found as the best binding compounds. The representative N6-cyclopropyl compound 6m was found to be a partial agonist, contrasting with the antagonist profiles of truncated 4′-oxo and 4′-thionucleosides. Computational docking highlighted 6m’s unique interaction with Thr94 at the A3AR binding site. This research not only advances our understanding of A3AR ligand interactions but also highlights the potential of truncated 4′-selenonucleosides as effective A3AR modulators.
期刊介绍:
ACS Medicinal Chemistry Letters is interested in receiving manuscripts that discuss various aspects of medicinal chemistry. The journal will publish studies that pertain to a broad range of subject matter, including compound design and optimization, biological evaluation, drug delivery, imaging agents, and pharmacology of both small and large bioactive molecules. Specific areas include but are not limited to:
Identification, synthesis, and optimization of lead biologically active molecules and drugs (small molecules and biologics)
Biological characterization of new molecular entities in the context of drug discovery
Computational, cheminformatics, and structural studies for the identification or SAR analysis of bioactive molecules, ligands and their targets, etc.
Novel and improved methodologies, including radiation biochemistry, with broad application to medicinal chemistry
Discovery technologies for biologically active molecules from both synthetic and natural (plant and other) sources
Pharmacokinetic/pharmacodynamic studies that address mechanisms underlying drug disposition and response
Pharmacogenetic and pharmacogenomic studies used to enhance drug design and the translation of medicinal chemistry into the clinic
Mechanistic drug metabolism and regulation of metabolic enzyme gene expression
Chemistry patents relevant to the medicinal chemistry field.